Zentalis Pharmaceuticals (NASDAQ:ZNTL) Announces Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) announced its quarterly earnings data on Monday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.24, FiscalAI reports.

Zentalis Pharmaceuticals Stock Up 1.2%

Zentalis Pharmaceuticals stock traded up $0.02 during trading on Monday, hitting $1.74. The stock had a trading volume of 1,273,694 shares, compared to its average volume of 1,531,419. Zentalis Pharmaceuticals has a 1 year low of $1.25 and a 1 year high of $6.95. The stock’s 50 day moving average is $2.74 and its two-hundred day moving average is $3.41. The stock has a market cap of $124.71 million, a price-to-earnings ratio of -0.89 and a beta of 1.91.

Analyst Upgrades and Downgrades

ZNTL has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, October 19th. Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Mizuho initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an “outperform” rating and a $8.00 price target for the company. Leerink Partners assumed coverage on shares of Zentalis Pharmaceuticals in a report on Monday, October 5th. They set an “outperform” rating and a $8.00 price objective for the company. Finally, Rodman & Renshaw initiated coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Insiders Place Their Bets

In other news, major shareholder Group Walters bought 4,335,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the completion of the transaction, the insider directly owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. This represents a 32.09% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 3.80% of the company’s stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.